DoD Ovarian Research Program FY25 anticipated funding opportunities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FY25 Defense Appropriations Act is anticipated to provide funding for the Ovarian Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members and all women impacted by this disease. The Congressionally Directed Medical Research Programs, or CDMRP, at the U.S. Army Medical Research and Development Command is the program office managing these anticipated FY25 funding opportunities.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

EC granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Elahere is the first and only folate receptor alpha-directed antibody drug conjugate medicine approved in the EU, as well as Iceland, Liechtenstein, Norway, and Northern Ireland.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login